Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)

v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Research And Development Expenses $ 5,451,287 $ 3,279,323 $ 10,356,965 $ 6,869,376  
Terms of license Agreement     Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines    
Deferred Revenue 10,000,000.0   $ 10,000,000.0    
Cash and cash equivalents 19,743,274   19,743,274   $ 10,867,050
Accounts receivable 196,487   196,487   $ 72,609
Cash and cash equivalent [Member]          
Cash and cash equivalents $ 19,700,000   19,700,000    
Research And Development Expenses [Member]          
Research And Development Expenses     $ 10,400,000 $ 6,900,000  
Warrants And Options [Member]          
Potentially Dilutive Securities Excluded From The Computation Of Eps 7,795,320   7,795,320